Transplantation of suicide gene modified allogeneic T lymphocytes is an approach to prevent T cell mediated GVHD while preserving the 'graft-versus-leukemia' (GVL) effect of an allograft. A prerequisite for such a therapy is the efficient transduction of T cells with suitable vectors. Since existing techniques allow only insufficient transduction of T cells, the development of more efficient gene transfer protocols into these cells is of great importance. We present here a protocol for the highly efficient transduction of human primary T cells at high densities (1 ؋ 10 6 cells/ml) by retroviral infection. The presented protocol allowed us to obtain transduction rates of more than 70% of CD3 ؉ cells after two cycles of infection. It is based on the use of FBS-free media for both the production of retrovirus-containing supernatant, as well as the cultivation of the primary T cells. Since the protocol presented here works just as efficiently under large scale conditions, it may easily be adapted to clinical needs and 'good manufacturing practice' (GMP) standards. Bone Marrow Transplantation (2000) 25, Suppl. 2, S96-S98.
Graft-versus-host disease (GVHD) triggered by immunecompetent donor T lymphocytes is one of the major complications after allogeneic bone marrow (BMT) and peripheral blood stem cell transplantation (PBCST). Ex vivo depletion of T cells effectively prevents GVHD, but the lack of these cells in the transplant increases graft rejection and infection risks, and decreases the adoptive graft-versus-leukemia effect (GVL). 1 It is thus a principal goal of clinicians to get rid of the unfavorable side-effects of allogeneic T cells while preserving their beneficial effects. One approach in this direction is the transfer of suicide genes to T cells that allow an inducible elimination of activated cells through a prodrug. 2, 3 A prerequisite for this approach is the efficient gene transfer into T cells. However, based on standard 4 In a bid to overcome this problem, different pseudotypes 5, 6 and infection protocols 5, 7, 8 for human T cells have been proposed. However, several shortcomings may hinder the clinical application of these protocols. First, existing protocols frequently use low cell densities (Ͻ2 ϫ 10 5 cells/ml) in order to obtain high transduction rates. Second, to our knowledge all protocols for human primary T cells published so far are based on the use of media supplemented with fetal bovine serum (FBS), a potent immunogen 9 and possible source of biological contamination. Third, most of the protocols include complex procedures and multiple infections. Taken together, these limitations would impede the adaptation of existing protocols to the transduction of large numbers of T-lymphocytes as needed in gene therapeutic protocols and the requirements of 'good manufacturing practice' (GMP).
We have developed an easy protocol for the efficient transduction of human primary T cells with retroviral vectors, for clinical application, using serum-free medium (SFM) for the generation of vector-containing supernatant, and SFM complemented with autologous serum during infection.
Materials and methods

Cell lines and vector production
Vectors were produced by cell lines PG13/⌬LNGFR+tk 10 and PG13/SF1⌬. 10 Producer cells were seeded at 1.5 ϫ 10 4 cells/cm 2 in DMEM (Life Technologies, Paisley, UK) + 10% FBS (PAA, Linz, Austria) and expanded for 72 h to confluence. After washing with PBS (Life Technologies), X-vivo 10 (BioWhittaker, Walkersville, USA) was incubated on the cell layer at 0.1 ml/cm 2 at 37°C. Supernatant was harvested after 6-12 h.
T cell stimulation and transduction
After Ficoll gradient centrifugation, 2 ϫ 10 6 /ml mononuclear cells (MNC) from buffy coats were activated with 10 ng/ml OKT-3 (Cilag, Neuss, Germany) and 100 U/ml IL-2 (PAN, Nürnberg, Germany) for 3 days. For infection, 3 ϫ 10 6 cells were incubated in 3 ml retrovirus containing supernatant. Infection was carried out in the presence of 4 g/ml protamine sulphate by overnight incubation at 37°C either in FN-coated or in normal tissue culture six-well plates. The latter were centrifuged for 1 h at 1000 g at 20°C before incubation at 37°C. Infection was repeated after 24 h.
Analysis of gene transfer efficiency
Gene transfer into primary T cells was determined 3 days after the second infection by double staining with anti-CD3 (Becton Dickinson, Heidelberg, Germany) and anti-NGF antibodies as described.
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Results
Retroviral vectors based on the Moloney murine leukaemia virus can only infect dividing cells. 12 Consequently, we tried different protocols for the stimulation of primary T cells. After Ficoll gradient centrifugation, MNC were incubated in various cultivation media supplemented with 100 U/ml interleukin-2 (IL-2). For T cell activation we used either OKT-3 alone (in solution or immobilized), or in combination with anti-CD28 antibodies. We determined the start of cell division by flow cytometry using PKH-26, a fluorescence dye incorporated into the cell membrane. Almost all T cells entered the cell cycle on day 3 after stimulation with OKT-3 (not shown). This corresponded well to our cell counting data demonstrating increasing T cell numbers after day 3. Also, activation was measured based on the expression of cell surface markers. We found that cells activated with the OKT3/anti-CD28 combination showed a remarkably higher expression of both CD25 and CD69 as determined by flow cytometry. However, gene transfer into T cells activated with OKT-3 alone was just as efficient, whereas slightly higher gene transfer was observed in cells activated using immobilized antibodies (data not shown).
During activation with OKT-3 and IL-2 (see above), cells were kept in various media: X-vivo 10, X-vivo 10 + 8% autologous serum (AS), RPMI 1640 + 10% FBS, RPMI 1640 + 8% AS. After 3 days, 10 6 cells/ml were resuspended in X-vivo 10-based retroviral vector containing supernatant (see above), and transduced as described in Materials and methods. In some experiments, additional stimulation with OKT-3 during the infection step was carried out. It was, however, of insignificant advantage (data not shown). Although efficient gene transfer was possible in the completely serum-free medium (X-vivo 10), additional autologous serum (8%) led to a remarkable increase of transduction efficiencies for both X-vivo 10 and RPMI 1640 (Figure 1) .
Based on these data, we then compared two different transduction protocols based on double infection either using the centrifugation protocol or fibronectin (CH-296)-coated tissue culture flasks. 11 Fibronectin, a cell matrix component, enhances gene transfer by retroviral vectors into different cell types probably due to co-localization of retroviral particles and target cells on specific fragments of the molecule. 13 We found up to 61% gene transfer using the centrifugation procedure and up to 79% on fibronectin (data not shown). This is consistent with our previous data showing a slight (approximately 25%) but significant increase of gene transfer into lymphocytes on FN.
11 Similar data were described by Pollok et al, 8, 14 where up to 90% of T cells were transduced on FN, although at comparatively low cell densities (Ͻ2 ϫ 10 5 /ml) and after triple infection.
In our last step, we adapted the centrifugation-based protocol to large scale conditions. We infected 1 ϫ 10 8 cells at a density of 1 × 10 6 cells/ml (ie 2 ϫ 100 ml supernatant). As shown for two different donors in Figure 2 , after 6 days in culture we obtained more than 6 ϫ 10 8 T cells, of which more than 60%, ie more than 3.5 ϫ 10 8 , were genetically modified. This shows that the protocol described here enables the transduction of large cell numbers as required for clinical applications.
Discussion
In summary, we have developed a protocol for the highly efficient transduction of human primary T cells, which meets the requirements for clinical application. The protocol is, to our knowledge, the first one, which avoids the use of FBS-containing media during T cell transduction. The easy handling procedures makes it highly compatible with the standards of good manufacturing practice (GMP), while allowing the transduction of target cells at comparatively high cell densities (1 ϫ 10 6 /ml). The use of the centrifugation protocol for clinical purposes may be favored by cost and handling factors. The fibronectin-based protocol, however, allows higher gene transfer and may be of advantage, when nearly pure populations of gene-modified cells are required without selection. According to previously published work 8, 14 and our own data (unpublished) more than 90% of the cells may be transduced after triple infection on fibronectin. In conclusion, we suggest that based on our data optimal protocols can be designed for both clinical and research purposes.
